FACULTY CO-CHAIRS
Linda A. DiMeglio, MD, MPH
Professor of Pediatrics
Pediatric Endocrinology & Diabetology
Riley Children’s Health
Indiana University School of Medicine
Indianapolis, Indiana
Kimber Simmons, MD, MPH, MSPH
Associate Professor of Pediatrics
Barbara Davis Center for Diabetes
University of Colorado, Anschutz Medical Campus
Aurora, Colorado
PROGRAM DESCRIPTION
This program provides a comprehensive expert overview of the critical role of screening and detection of early-stage type 1 diabetes (T1D), along with the importance of monitoring post-screening to identify individuals who may benefit from treatment with disease-modifying therapies (DMTs). In addition, the program explores the evidence with DMTs to delay T1D progression, as well as patient selection and practical considerations for their application to patient care. Through engaging animations and case-based discussions, this program will help reinforce key concepts in early stage T1D.
TARGET AUDIENCE
This activity is designed to meet the educational needs of multidisciplinary clinicians who refer, treat or see patients with or at high risk for T1D, including primary care clinicians, pediatricians, pediatric & adult endocrinologists, diabetes educators, infusion professionals and other allied healthcare professionals.
LEARNING OBJECTIVES
After completing the CME activity, learners should be better able to:
- Incorporate evidence-based strategies for presymptomatic T1D screening into routine clinical practice to improve early detection.
- Interpret T1D screening results and effectively communicate next steps to support patient education and inform treatment decisions.
- Identify appropriate patients who would benefit from treatment with disease-modifying therapies for delaying T1D progression based on clinical evidence.
- Implement protocols to support safe and efficient administration of disease-modifying therapies for T1D according to guidance and patient-specific factors.
JOINT ACCREDITATION STATEMENT
In support of improving patient care, Med Learning Group is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
PHYSICIAN CREDIT DESIGNATION STATEMENT
Med Learning Group designates this enduring activity for a maximum of 1.5 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.
NURSES (ANCC) CREDIT DESIGNATION
Med Learning Group designates this activity for a maximum of 1.5 ANCC contact hours.
COMMISSION ON DIETETIC REGISTRATION (CDR) CREDIT DESIGNATION
Med Learning Group designates this activity for a maximum of 1.5 CPEU.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF FINANCIAL RELATIONSHIPS
| Speaker | Relationships | Manufacturer |
| Linda A DiMeglio, MD, MPH | Consulting Fee | Abata, Tandem |
| Contracted research | Dompe, Lilly, MannKind, Sanofi, and Zealand | |
| Stock | Lilly | |
| DSMB member | Lilly and Merck & Co., Inc. (non-diabetes indications) | |
| Kimber Simmons, MD, MPH, MSPH | Consulting Fee | Sanofi and Shoreline Biosciences |
| Contracted research | Sanofi |
All relevant financial relationships have been mitigated.
Content Review
The content of this activity was independently peer reviewed by a physician and nurse reviewer.
Individuals in Control of the Content of the Activity
The individuals in control of the content of this activity have reported the following financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CE activity:
- Matthew Frese, MBA, CEO of Med Learning Group, has nothing to disclose.
- Lauren Welch, MA, Senior VP of Operations for Med Learning Group, has nothing to disclose.
- Kelly Vicci, RN, BSN, has nothing to disclose.
- A medical reviewer from CME Peer Review LLC, has nothing to disclose.
- Shpetim Karandrea, PhD, Medical Director for Med Learning Group, has nothing to disclose.
- Tom Bregartner, MBA, VP of Outcomes and Accreditation for Med Learning Group, has nothing to disclose.
- Aimee Meissner, Outcomes and Accreditation Coordinator for Med Learning Group, has nothing to disclose.
- Felecia Beachum, Sr. Program Manager for Med Learning Group, has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CE activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States. During the course of this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CE credit for this activity. In order to obtain your certificate for the mentioned accreditation, participants need to successfully complete the associated pre/post activities and evaluation. Your certificate will be provided as a downloadable file.
DISCLAIMER
Med Learning Group makes every effort to develop CE activities that are scientifically based. This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making expertise before applying any information, whether provided here or by others, for any professional use.
For CE questions, please contact Med Learning Group at [email protected]
Contact this CE provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at [email protected]
RELEASED DATE: July 16, 2025
EXPIRATION DATE: July 16, 2026
Copyright © 2025 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.
